• 1
    Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera. JAMA 1965; 191: 5416.
  • 2
    Bonino F, Piratvisuth T, Brunetto MR, Liaw YF. Diagnostic markers of chronic hepatitis B infection and disease. Antivir Ther 2010; 15(Suppl. 3): 3544.
  • 3
    Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH. Compact organization of the hepatitis B virus genome. Hepatology 1989; 9: 3227.
  • 4
    Tassopoulos NC, Papatheodoridis GV, Kalantzakis Y, et al. Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay. J Hepatol 1997; 26: 149.
  • 5
    Perrillo R, Satheesh N. Hepatitis B. In: Boyer TD, Wright T, Manns MP, eds. Zakim and Boyer's Hepatology. A Textbook of Liver Disease, 5th edn. Amsterdam: Elsevier, 2006; 63563.
  • 6
    Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 2001; 34: 194203.
  • 7
    Kim BK, Han KH, Ahn SH. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. Digestion 2011; 84(Suppl. 1): 2934.
  • 8
    Craxì A, Marino L, Aragona E, Patti C. IgM anti-HBc in acute and chronic hepatitis B virus (HBV) infection: diagnostic value and correlation with viral replication and disease activity. Boll Ist Sieroter Milan 1988; 67: 27582.
  • 9
    Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 24357.
  • 10
    El Chaar M, Candotti D, Crowther RA, Allai JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010; 52: 160010.
  • 11
    Raimondo G, Pollicino T, Cacciola I, Quadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 16070.
  • 12
    Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142: 130313.
  • 13
    Lok A. Occult hepatitis B virus infection: diagnosis, implications and management? Gastroenterol Hepatol 2004; 19: S1147.
  • 14
    Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 192738.
  • 15
    Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 105675.
  • 16
    Chevaliez S, Bouvier-Alias M, Laperche S, Hézode C, Pawlotsky JM. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2010; 48: 36417.
  • 17
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 18
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 -summary of a workshop. Gastroenterology 2001; 120: 182853.
  • 19
    Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 2012; 47: 81422.
  • 20
    Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis 2012; 16: 34769.
  • 21
    Cornberg M, Protzer U, Dollinger MM, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV) infection: upgrade of the guideline. Z Gastroenterol 2007; 45: 52574.
  • 22
    Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 40515.
  • 23
    Caliendo AM, Valsamakis A, Bremer JW, et al. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol 2011; 49: 28548.
  • 24
    Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012; 32: 133341.
  • 25
    EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 16785.
  • 26
    Lok A, Mc Mahon B. AASLD Practice Guidelines. Chronic hepatitis B: an update 2009. Hepatology 2009; 50: 136.
  • 27
    Liaw JF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 26383.
  • 28
    Gadano A, Daruich J, Cheinquer H, et al. Guía Latinoamericana de Manejo de la Hepatitis Crónica B. Acta Gastroenterol Latinoam 2011; 41: 34050.
  • 29
    Fainboim H, Marciano S, Di Benedetto N, Gadano A. Consenso Argentino de Hepatitis B. Acta Gastroenenterol Latinam 2013; 43: 5974.
  • 30
    Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395401.
  • 31
    Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 50813.
  • 32
    Frosner GG, Schomerus H, Wiedmann KH, et al. Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection. Eur J Clin Microbiol 1982; 1: 528.
  • 33
    Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514.
  • 34
    Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 48390.
  • 35
    Martinot-Perigaux M, Lapalus M, Asselah T, Marcellin P. How to distinguish HBeAg negative chronic hepatitis B, with high risk of reactivation, from inactive carriers: is there a place for HBsAg quantification? Hepatology 2012; 56(Suppl.): 434A.
  • 36
    Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013; 33(Suppl. 1): 12532.
  • 37
    Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010; 25: 1498506.
  • 38
    Chan HL. Response-guided therapy by hepatitis B surface antigen level for peginterferon therapy: what is next? J Gastroenterol Hepatol 2012; 27: 4201.
  • 39
    Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 11517.
  • 40
    Sonneveld M, Zoutendijk R, Flink H, et al. Monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 2013; 56: 1005.
  • 41
    Sonneveld MJ, Hansen BE, Janssen HL, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 87280.
  • 42
    Wu Z, Sheng J, Li L. Improvement of HBsAg Loss by additional PEG IFN in Nucleosides Analogs treated Chronic Hepatitis B patients. Hepatology 2012; 56(Suppl.): 404A.
  • 43
    Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterol 2012; 142: 51320.
  • 44
    Lee DH, Cho Y, Seo JW, et al. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 2013; 56: 8490.
  • 45
    Zhang Q, Lapalus M, Asselah T, et al. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg positive chronic hepatitis B patients. J Viral Hepat 2014; 21: 52532.
  • 46
    Pourkarim MR, Amini-Bavil-Olyaee S, Lemey P, Maes P, Van Ranst M. Are hepatitis B virus “subgenotypes” defined accurately? J Clin Virol 2010; 47: 35660.
  • 47
    Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 155468.
  • 48
    Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010; 15(Suppl. 3): 2533.
  • 49
    Devesa M, Pujol FH. Hepatitis B virus genetic diversity in Latin America. Virus Res 2007; 127: 17784.
  • 50
    Scalia G, Russo R, Palermo I, et al. Clinical, virological and epidemiological aspects of acute B hepatitis in the Catania area (Italy). Infez Med 2010; 18: 16974.
  • 51
    Deterding K, Constantinescu I, Nedelcu FD, et al. Prevalence of HBV genotypes in Central and Eastern Europe. J Med Virol 2008; 80: 170711.
  • 52
    Pezzano SC, Torres C, Fainboim HA, et al. Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes. Clin Microbiol Infect 2011; 17: 22331.
  • 53
    Bessone F, Fay F, Benetti S, et al. Estudio observacional y prospectivo de genotipos del HBV: correlacion con la viremia y el estado del antigeno e. Acta Latinoam Gasroenterol 2009; 39: 15.
  • 54
    Bessone F, Fay F, Benetti S, et al. High prevalence of genotype A in patients with chronic hepatitis B in Rosario, Argentina. Ann Hepatol 2008; 7: 265.
  • 55
    Beggel B, Neumann-Fraune M, Döring M, et al. Genotyping hepatitis B virus dual infections using population-based sequence data. J Gen Virol 2012; 93(Pt. 9): 1899907.
  • 56
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 9981002.
  • 57
    Furusyo N, Nakashima H, Kashiwagi K, et al. Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. Am J Trop Med Hyg 2002; 67: 1517.
  • 58
    Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 5549.
  • 59
    Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 14948.
  • 60
    Raimondi S, Maisonneuve P, Bruno S, Mondelli M. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010; 52: 4419.
  • 61
    Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis 2012; 65: 47682.
  • 62
    Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 14527.
  • 63
    McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 75968.
  • 64
    Bessone F. Hepatitis crónica B (HCB): ¿cuál es la mejor opción de tratamiento? Acta Latin Gastroenterol 2008; 38: 15260.
  • 65
    Bessone F. Manejo actual de la hepatitis crónica B. 2010. Available at Accessed 24 February 2014.
  • 66
    Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008; 46: 171623.
  • 67
    Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 140815.
  • 68
    Chang TT, Chao YC, Gorbakov VV, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009; 16: 7849.
  • 69
    Strassburg M, Manns M. Approaches to liver biopsy techniques—revisited. Sem Liver Dis 2006; 26: 31827.
  • 70
    Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 7607.
  • 71
    Han KH, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008; 2: 1859.
  • 72
    Fainboim H, Schroder T, Paz S, et al. Portadores crónicos HBV e negativos: correlación de los niveles replicativos del HBV con indicación histológica de inicio de tratamiento antiviral y grado de fibrosis. Acta Latin Gastroenerol 2009; 39 (Suppl.): S 8.
  • 73
    Fainboim H, Schroder T, Paz S, et al. Significado de la visualizacion por ultrasonografia de las adenopatias del ligamento hepato-duodenal en pacientes portadores cronicos de virus B. Acta Latin Gastroenerol 2009; 39 (Suppl.): S 15.
  • 74
    Schiff E, Lee S, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 2746.
  • 75
    Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
  • 76
    Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest–ActiTest) and viral load. PLoS ONE 2008; 3: e2573.
  • 77
    Poynard T. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2011; 54: 5867.
  • 78
    Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 101321.
  • 79
    Lim SG, Cho SW, Lee YC, et al. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. Hepatogastroenterology 2011; 58: 53945.
  • 80
    Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a metaanalysis of diagnostic accuracy. J Hepatol 2011; 54: 6509.
  • 81
    Ferraioli G, Tinelli C, Bello BD, et al. Performance of liver stiffness measurements by transient elastography in chronic hepatitis. World J Gastroenterol 2013; 19: 4956.
  • 82
    Chang J, Lui H, Tan C, Chow W. Transient elastography (Fibroscan) is reliable for non - invasive diagnosis of significant fibrosis in chronic hepatitis B with mild transaminitis but becomes less reliable at higher ALT levels. Hepatology 2008; 50: 501A.
  • 83
    Fung J, Seto WK, Lai CHL, et al. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. J Hepatol 2011; 54: 195200.
  • 84
    Bessone F, Benetti S, Fay F, et al. Mayor número de pacientes con hepatitis crónica B tienen indicación de tratamiento según las guías Europeas comparado con otras guías internacionales. Acta Gastroenterol Latinoam 2011; 41(sup 1): S610.